Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 2:10:851087.
doi: 10.3389/fcell.2022.851087. eCollection 2022.

PROTACs: The Future of Leukemia Therapeutics

Zubair Anwar  1 , Muhammad Shahzad Ali  2 , Antonio Galvano  1 , Alessandro Perez  1 , Maria La Mantia  1 , Ihtisham Bukhari  3 , Bartlomiej Swiatczak  4
Affiliations
Review

PROTACs: The Future of Leukemia Therapeutics

Zubair Anwar et al. Front Cell Dev Biol. .

Abstract

The fight to find effective, long-lasting treatments for cancer has led many researchers to consider protein degrading entities. Recent developments in PROteolysis TArgeting Chimeras (PROTACs) have signified their potential as possible cancer therapies. PROTACs are small molecule, protein degraders that function by hijacking the built-in Ubiquitin-Proteasome pathway. This review mainly focuses on the general design and functioning of PROTACs as well as current advancements in the development of PROTACs as anticancer therapies. Particular emphasis is given to PROTACs designed against various types of Leukemia/Blood malignancies.

Keywords: PROTACs; anticancer therapeutics; cancer; leukemia; linker.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
The PROTACs mode of action, involving ubiquitination and eventual degradation of POI.
See this image and copyright information in PMC

References

    1. An S., Fu L. (2018). Small-molecule PROTACs: An Emerging and Promising Approach for the Development of Targeted Therapy Drugs. EBioMedicine 36, 553–562. 10.1016/j.ebiom.2018.09.005 PubMed Abstract | 10.1016/j.ebiom.2018.09.005 | Google Scholar - DOI - DOI - PMC - PubMed
    1. Anderson N. A., Cryan J., Ahmed A., Dai H., McGonagle G. A., Rozier C., et al. (2020). Selective CDK6 Degradation Mediated by Cereblon, VHL, and Novel IAP-Recruiting PROTACs. Bioorg. Med. Chem. Lett. 30 (9), 127106. 10.1016/j.bmcl.2020.127106 PubMed Abstract | 10.1016/j.bmcl.2020.127106 | Google Scholar - DOI - DOI - PubMed
    1. Bai L., Zhou B., Yang C.-Y., Ji J., McEachern D., Przybranowski S., et al. (2017). Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer. Cancer Res. 77 (9), 2476–2487. 10.1158/0008-5472.CAN-16-2622 PubMed Abstract | 10.1158/0008-5472.CAN-16-2622 | Google Scholar - DOI - DOI - PMC - PubMed
    1. Bill M., Goda C., Pepe F., Ozer H. G., McNeil B., Zhang X., et al. (2021). Targeting BRD4 in Acute Myeloid Leukemia with Partial Tandem Duplication of the MLL Gene. haematol 106 (9), 2527–2532. 10.3324/haematol.2020.271627 10.3324/haematol.2020.271627 | Google Scholar - DOI - DOI - PMC - PubMed
    1. Bond M. J., Chu L., Nalawansha D. A., Li K., Crews C. M. (2020). Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs. ACS Cent. Sci. 6 (8), 1367–1375. 10.1021/acscentsci.0c00411 PubMed Abstract | 10.1021/acscentsci.0c00411 | Google Scholar - DOI - DOI - PMC - PubMed

LinkOut - more resources